Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015

Abstract

IMPORTANCE Cancer treatments are associated with subsequent neoplasms in survivors of childhood cancer. It is unknown whether temporal changes in therapy are associated with changes in subsequent neoplasm risk.OBJECTIVE To quantify the association between temporal changes in treatment dosing and subsequent neoplasm risk.DESIGN, SETTING, AND PARTICIPANTS Retrospective, multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United States and Canada between 1970-1999, with follow-up through December 2015.EXPOSURES Radiation and chemotherapy dose changes over time.MAIN OUTCOMES AND MEASURES Subsequent neoplasm 15-year cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancies, compared by treatment decade. Multivariable models assessed relative rates (RRs) of subsequent neoplasms by 5-year increments, adjusting for demographic and clinical characteristics. Mediation analyses assessed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable modifications. RESULTS Among 23 603 survivors of childhood cancer (mean age at diagnosis, 7.7 years; 46% female) the most common initial diagnoses were acute lymphoblastic leukemia, Hodgkin lymphoma, and astrocytoma. During a mean follow-up of 20.5 years (374 638 person-years at risk), 1639 survivors experienced 3115 subsequent neoplasms, including 1026 malignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers. The most common subsequent malignancies were breast and thyroid cancers. Proportions of individuals receiving radiation decreased (77% for 1970s vs 33% for 1990s), as did median dose (30 Gy [interquartile range, 24-44] for 1970s vs 26 Gy [interquartile range, 18-45] for 1990s). Fifteen-year cumulative incidence of subsequent malignancies decreased by decade of diagnosis (2.1% [95% CI, 1.7%-2.4%] for 1970s, 1.7% [95% CI, 1.5%-2.0%] for 1980s, 1.3% [95% CI, 1.1%-1.5%] for 1990s). Reference absolute rates per 1000 person-years were 1.12 (95% CI, 0.84-1.57) for subsequent malignancies, 0.16 (95% CI, 0.06-0.41) for meningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years). Standardized incidence ratios declined for subsequent malignancies over treatment decades, with advancing attained age. Relative rates declined with each 5-year increment for subsequent malignancies (RR, 0.87 [95% CI, 0.82-0.93]; P < .001), meningiomas (RR, 0.85 [95% CI, 0.75-0.97]; P = .03), and nonmelanoma skin cancers (RR, 0.75 [95% CI, 0.67-0.84]; P < .001). Radiation dose changes were associated with reduced risk for subsequent malignancies, meningiomas, and nonmelanoma skin cancers.CONCLUSIONS AND RELEVANCE Among survivors of childhood cancer, the risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s, although the risk was lower compar...

Thyroid Sequelae of Pediatric Cancer Therapy

“…1). Thyroid cancer, specifically papillary thyroid carcinoma (PTC), is one of the most frequently diagnosed subsequent primary malignancies in childhood cancer survivors [28, 85, 86]. Survivors of childhood Hodgkin disease, for example, are 18.3-fold more likely to develop PTC [26], although benign thyroid nodules are still more common [31].…”

“…Typically, the latency period is long, and studies from the CCSS and the British CCSS cohorts showed a median time to occurrence around 19–20 years after treatment of the first primary cancer [32, 85]. In some studies, the reported shorter latency periods could be in part attributed to the incorporation of routine ultrasound screening in at-risk cancer survivors [86, 89].…”

LncRNA HOTAIR/miR‐613/c‐met axis modulated epithelial‐mesenchymal transition of retinoblastoma cells

“…Currently, since most children have entered late‐stage retinoblastoma that represented high chance of ocular extraction, early diagnosis and treatment for retinoblastoma appeared to be quite critical 2, 3. To save children's visual function,4 diverse treatment strategies have been developed for varying degrees of retinoblastoma 5.…”

Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population‐based assessment

“…2 However, curative therapy for childhood malignancies places many survivors at increased risk for late effects of treatment, including second primary malignancies (SPMs). [4][5][6][7][8][9] Although fewer than 3% of childhood cancer survivors develop an SPM within 15 years of their initial diagnosis, 4 the cumulative incidence approaches 10% by 30 years after the diagnosis in high-risk populations. 3 In particular, patients treated with radiotherapy, anthracyclines, platinum agents, or alkylating agents are vulnerable to subsequent neoplasms.…”